SCHEMBL2899147

SCHEMBL2899147

CN1C(C)(C)CC(n2c(=O)c(O)c3n(c2=O)CCN(Cc2ccc(F)cc2)C3=O)CC1(C)C

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.38
GRM2 Q14416 1/20 0.38
TP53 P04637 4/20 0.38
LMNA P02545 3/20 0.37
POLB P06746 2/20 0.36
CYP2D6 P10635 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
RAB9A P51151 1/20 0.35
ALDH1A1 P00352 2/20 0.34
AKR1B1 P15121 1/20 0.34
PKM P14618 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
THRB P10828 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2898704 0.84 JAK2 (0.41) KCNH2GRM2TP53LMNAPOLB
SCHEMBL2898715 0.83 NPSR1 (0.48) KCNH2GRM2TP53LMNAPOLB
SCHEMBL2898773 0.83 TSHR (0.46) KCNH2GRM2TP53LMNAPOLB
SCHEMBL2898693 0.83 NPSR1 (0.47) KCNH2GRM2TP53LMNAPOLB
SCHEMBL2900488 0.83 NPSR1 (0.47) KCNH2GRM2TP53LMNAPOLB
SCHEMBL2895568 0.82 TSHR (0.42) KCNH2GRM2TP53LMNAPOLB
SCHEMBL2895565 0.82 TSHR (0.42) KCNH2GRM2TP53LMNAPOLB
SCHEMBL2896908 0.81 KCNH2 (0.41) KCNH2GRM2TP53LMNAPOLB
SCHEMBL2895486 0.81 LMNA (0.40) KCNH2GRM2TP53LMNAPOLB
SCHEMBL2900613 0.81 KCNH2 (0.39) KCNH2GRM2TP53LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820680-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2010-10-26 US claimed
EP-1725102-A4 HIV INTEGRASE INHIBITORS MERCK & CO INC (US) 2009-04-29 EP claimed
US-20080009490-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-10 US claimed
EP-1725102-A1 HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2006-11-29 EP claimed
WO-2005092099-A1 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-10-06 WO claimed
US-7820680-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2010-10-26 US disclosed
US-7820680-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2010-10-26 US disclosed
US-20080009490-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-10 US disclosed
US-20080009490-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009490-A1 Hiv Integrase Inhibitors TYMS, UNG, TYMP KCNH2 3441/4885GRM2 4668/4885TP53 564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.